Skip to ContentSkip to Navigation
Research Department of Genetics
University Medical Center Groningen

Testing options for an asymptomatic person with genetic risk

Targeted sequencing versus whole genome sequencing
30 June 2014

'Jim Mathis is a 45-year-old health-conscious man who has been a patient in an internal medicine–primary care practice for several years. At today's visit, he talks about the family tree that he has sketched out and his discovery that three of his relatives had cancer — one had breast cancer, one ovarian cancer, and one prostate cancer' .... Discussion in the NEJM of two testing options, i.e. targeted versus whole genome sequencing

Reply by Irene van Langen, Tom de Koning, Conny van Ravenswaaij, Cisca Wijmenga, Rolf Sijmons and Richard Sinke:
'Which technique is most appropriate to answer the question depends on performances and costs and the trade off between advantages and harms. One of the advantages or risks, depending on the viewpoints of those involved, could be the finding of pathogenic mutations not related to the diagnostic question at hand (incidental findings). If such mutations are known to be associated to diseases with preventive options (like CVD), this clearly would be advantageous information for the counselee and his or her relatives, provided that he or she consciously consented.

Since we consider the analysis of ‘actionable’ genes - not related to the initial medical indication - to be screening rather than diagnostic testing, the health care system should, in our view, not yet be burdened with its cost, even in a rich country like ours. But, if patients are willing to pay for this screening and counseling themselves, who are we to judge this negatively? If the costs of sequencing, including the interpretation efforts and number of unclassifiable variants, continue to decrease, whole genome sequencing (WGS) rather than gene panels or whole exome sequencing (WES' may indeed become the optimal technique. We (at the Dept of Genetics, UMCG, the Netherlands) still expect this to take several more years.'

See Full case vignette, New England Journal of Medicine, 19 June 2014, with readers´ comments

Last modified:18 December 2023 08.30 a.m.

More news

  • 29 February 2024

    Vici grants for four UG/UMCG scientists

    The Dutch Research Council (NWO) has awarded Vici grants, worth up to €1.5 million each, to Nathalie Katsonis, Edwin Otten and Alexandra Zhernakova. Professor of Coastal Ecology Tjisse van der Heide has also received a Vici grant for research he...

  • 27 February 2024

    New study finds early life economic conditions impact risk of type-2 diabetes in adulthood

    A new study by current and former FEB researchers Rob Alessie, Viola Angelini, Gerard van den Berg, Jochen Mierau and Gianmaria Niccodemi sheds light on the long-term health implications of economic conditions in early life. The study, titled...

  • 05 February 2024

    Three UG researchers nominated for Woman in the Media Award 2023

    Three women affiliated with the RUG/UMCG have been nominated for the Woman in the Media Award 2023: Léonie de Jonge, Myrthe Hol and Iris Sommer. This election aims to encourage female experts and public figures to appear more in the media and to...